Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances

News provided by

Feb 14, 2024, 14:30 ET

DUBLIN, Feb. 14, 2024 /PRNewswire/ -- The "Biosimilar Monoclonal Antibodies Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.

The expansion of the biosimilar monoclonal antibodies market to $9.25 billion in 2024, representing a compound annual growth rate (CAGR) of 15.1%, signals robust advancements and escalating demand within the pharmaceutical industry.

The new research study offers valuable insights into the key dynamics of the biosimilar monoclonal antibodies sector, with particular emphasis on the historical growth of the market driven by patent expirations, rising disease prevalence, and evolving government policies supporting biosimilar applications.

Data within the report underscore the growing receptiveness towards biosimilars among healthcare professionals and patients alike, which has significantly contributed to the industry's upward trajectory.

Future Market Growth Powered by Biologics and Personalized Therapy Advances

Looking ahead, the market is anticipated to reach $12.79 billion by 2028, flourishing at a CAGR of 8.5%. The research suggests that the increase in investment towards biologic medication development, the surge in chronic diseases, and the necessity for cost-effective treatment options will bolster the market growth.

The market is also primed to witness a shift towards personalized biosimilar therapies and an upturn in strategic collaborations within the sector, leading to novel healthcare solutions.

Key Trends and Innovations Shaping the Biosimilar Monoclonal Antibodies Sector

The research recognizes a range of promising trends and innovations, including the extensive development of therapeutic applications, the inception of specialized delivery devices, and the emergence of biobetters. These advancements are set to redefine the scope of biosimilar monoclonal antibodies, enhancing patient outcomes and widening the spectrum of treatable conditions.

Impact of Chronic Diseases and Aging Demographics on Market Growth

The omnipresence of chronic illnesses such as cancer and autoimmune diseases necessitates the continued demand for biosimilar monoclonal antibodies, with therapeutic offerings such as trastuzumab, bevacizumab, and rituximab at the forefront.
The burgeoning geriatric population amplifies the need for accessible and affordable therapeutic options, thereby fuelling the expansion of the biosimilars market.

Strategic Movements within the Biosimilar Monoclonal Antibodies Ecosystem

Recent industry movements underscore the strategic intent and dynamics within the biosimilar monoclonal antibodies space. For instance, the consolidation of Biocon Biologics Ltd.'s leadership through strategic acquisitions exemplifies the sector's ambitious commercial endeavors.

Major players, spanning diverse regions and specializing in diversified biopharmaceutical offerings, are central to driving innovation and ensuring the availability of biosimilars on a global scale.

Detailed Regional Analysis and Type Segmentation

The comprehensive research encompasses data from crucial regions including North America, Asia-Pacific, and Europe, investigating country-specific markets and unique local trends. The report segments the market into synthetic chemicals, biopharmaceuticals, among others, providing clarity on each segment's influence and relevance in the current biosimilar monoclonal antibodies landscape.

The report details the fabrication and sales processes of key biosimilar monoclonal antibodies such as Blitzima, Ritemvia, Rituzena, and Truxima, underlining the 'factory gate values.'

It delineates market values, emphasizing actual revenue collected by enterprises and the significance of the goods and services traded within the discussed industry domains.

Companies Profiled

Pfizer Inc.
Novartis AG
AbbVie Inc.
Coherus BioSciences
Biocon Limited
Amgen Inc.
Boehringer Ingelheim International GmbH
Celltrion Inc.
BioXpress Therapeutics SA
Intas Pharmaceuticals Limited
Genor BioPharma Co. Ltd.
BIOCAD
Dr. Reddy's Laboratories Ltd.
3SBio Inc.
Reliance Life Sciences
Hisun Pharmaceuticals
Celgen Biopharmaceuticals
Torrent Pharmaceuticals Ltd.
Cadila Healthcare Ltd.
Shanghai Henlius Biotech Inc.
Teva Pharmaceutical Industries Ltd.
Alvotech
Xentria Inc.
Lazuline Biotech Private Limited
Epygen Biotech Pvt Ltd.
Mabpharm Limitied
Qilu Pharmaceutical Co. Ltd.
Chiatai Tianqing Pharmaceutical Group Co. Ltd.
YL Biologics Ltd.
Aprogen Biologics
UNDBIO Co Ltd.
Samsung Bioepis Co. Ltd.
ISU Abxis Corp.
Bio-Rad Laboratories Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ynbzow

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets